LGP5 LOA

Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis. According to…

Denosumab biosimilar by Lupin for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Lupin and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData,…

23ME610 by 23AndMe Holding for Merkel Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,…

23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma. According to…

Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval

Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According to…

Vorolanib by Betta Pharmaceuticals for Thymic Carcinoma: Likelihood of Approval

Vorolanib is under clinical development by Betta Pharmaceuticals and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase…

Squaric acid dibutyl ester by Squarex Pharmaceutical for Herpes Labialis (Oral Herpes): Likelihood of Approval

Squaric acid dibutyl ester is under clinical development by Squarex Pharmaceutical and currently in Phase I for Herpes Labialis (Oral…

Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Filament Health and currently in Phase I for Treatment Resistant Depression. According to GlobalData,…

PF-07872412 by Pfizer for Streptococcal Pneumonia: Likelihood of Approval

PF-07872412 is under clinical development by Pfizer and currently in Phase I for Streptococcal Pneumonia. According to GlobalData, Phase I…

INV-347 by Inversago Pharma for Obesity: Likelihood of Approval

INV-347 is under clinical development by Inversago Pharma and currently in Phase I for Obesity. According to GlobalData, Phase I…